Siemens Healthineers testosterone test receives CDC certification
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- AMD shares fall amid AI chip sector selloff
- Alphabet shares drop ahead of earnings next week
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
CDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access to Gold Standard Equivalent Results
May 4, 2026 9:30 AM EDTTarrytown, NY, USA, May 04, 2026 (GLOBE NEWSWIRE) --
The Atellica TSTII Testosterone assay is the only immunoassay with CDC HoST-TT CertificationCertification reaffirms assay results are aligned with specialized mass spectrometry testing methodThe immunoassay test is a broadly available, economical option for patients and laboratoriesSiemens Healthineers announced its Atellica IM Testosterone II (TSTII) assay has achieved certification through the Centers for Disease Control and Prevention (CDC) Hormone Standardization Program for Total Testosterone (HoSt-TT). This certifies that the Atellica IM TSTII immunoassays test results are... More



